Sidereal Therapeutics

Sidereal Therapeutics is a private, preclinical-stage biotechnology company developing first-in-class therapeutics for acute kidney injury and other iron-mediated disorders. The company is focused on interventions that address iron overload biology and related kidney damage, with the goal of preventing acute injury from progressing to chronic disease. Its lead disclosed program, SIDE-100, is described as a biologic intended to harness the body's immune defenses and protect against iron-induced acute kidney injury. Sidereal appears to be an emerging kidney-focused biotech built around translational science in iron dysregulation and organ protection.